Literature DB >> 24729087

CD 152 gene polymorphisms and risk of osteosarcoma in Chinese population.

Zhengqi Chang1, Ruoxian Song, Songfeng Xu, Ming Xu, Xiuchun Yu.   

Abstract

Osteosarcoma has become a health threat for adolescents and young adults. To identify the genetic risk factor for the malignancy is in urgent need. Several studies have investigated the role of CD 152 polymorphisms in osteosarcoma in a sample of Chinese population. However, the association is poorly defined due to lack of a sufficiently large sample. In this study, we performed a meta-analysis of all CD 152 polymorphisms that had been implicated in osteosarcoma to examine the association. We searched the electronic MEDLINE database until December 31, 2013, to identify the studies regarding the association between CD 152 polymorphisms and osteosarcoma. Inclusion criteria were followed in the selection of eligible study. The genotypic and allelic data were collected from all studies included to evaluate the risk of osteosarcoma (odds ratio, OR). We found statistically significant evidence of the studied CD 152 polymorphisms and increased risk of osteosarcoma in homozygous (OR = 1.79, 95 % CI = 1.40-2.29, P = 0.958), recessive (OR = 1.77, 95 % CI = 1.40-2.25, P = 0.899), and allele model (OR = 1.21, 95 % CI = 1.09-1.34, P = 1.000). This increased risk was also revealed in single nucleotide polymorphism (SNP) +49G>A and SNP 326G>A. Our meta-analysis indicates that there may be an association between CD 152 polymorphisms and risk of osteosarcoma in Chinese population. Further validation of the observation is necessary.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24729087     DOI: 10.1007/s13277-014-1891-3

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  30 in total

1.  High incidence of CTLA-4 AA (CT60) polymorphism in renal cell cancer.

Authors:  Jose M Cozar; Jose M Romero; Natalia Aptsiauri; Fernando Vazquez; Jose R Vilchez; Miguel Tallada; Federico Garrido; Francisco Ruiz-Cabello
Journal:  Hum Immunol       Date:  2007-06-06       Impact factor: 2.850

2.  Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade.

Authors:  Ajay V Maker; Peter Attia; Steven A Rosenberg
Journal:  J Immunol       Date:  2005-12-01       Impact factor: 5.422

Review 3.  Cancer immunoediting: from immunosurveillance to tumor escape.

Authors:  Gavin P Dunn; Allen T Bruce; Hiroaki Ikeda; Lloyd J Old; Robert D Schreiber
Journal:  Nat Immunol       Date:  2002-11       Impact factor: 25.606

4.  Association of T-cell regulatory gene polymorphisms with oral squamous cell carcinoma.

Authors:  Peer W Kämmerer; Takeshi Toyoshima; Fabian Schöder; Philipp Kämmerer; Kathrin Kuhr; Jürgen Brieger; Bilal Al-Nawas
Journal:  Oral Oncol       Date:  2010-07       Impact factor: 5.337

5.  CTLA-4 can function as a negative regulator of T cell activation.

Authors:  T L Walunas; D J Lenschow; C Y Bakker; P S Linsley; G J Freeman; J M Green; C B Thompson; J A Bluestone
Journal:  Immunity       Date:  1994-08       Impact factor: 31.745

6.  Significant association between cytotoxic T lymphocyte antigen 4 +49G>A polymorphism and risk of malignant bone tumors.

Authors:  Fengbin Yu; Jinhao Miao
Journal:  Tumour Biol       Date:  2013-07-31

7.  Cytotoxic T-lymphocyte antigen-4 genetic variants and risk of Ewing's sarcoma.

Authors:  Dapeng Feng; Xinghai Yang; Shufeng Li; Tielong Liu; Zhipeng Wu; Yuanlin Song; Jian Wang; Wenwu Gao; Quan Huang; Wending Huang; Wei Zheng; Jianru Xiao
Journal:  Genet Test Mol Biomarkers       Date:  2013-03-12

8.  Cytotoxic T lymphocyte antigen-4 promoter variants in breast cancer.

Authors:  N Erfani; M Razmkhah; A R Talei; A M Pezeshki; M Doroudchi; A Monabati; A Ghaderi
Journal:  Cancer Genet Cytogenet       Date:  2006-03

9.  Bone cancers.

Authors:  H D Dorfman; B Czerniak
Journal:  Cancer       Date:  1995-01-01       Impact factor: 6.860

10.  CD28-mediated costimulation of interleukin 2 (IL-2) production plays a critical role in T cell priming for IL-4 and interferon gamma production.

Authors:  R A Seder; R N Germain; P S Linsley; W E Paul
Journal:  J Exp Med       Date:  1994-01-01       Impact factor: 14.307

View more
  3 in total

1.  Single nucleotide polymorphisms of HER2 related to osteosarcoma susceptibility.

Authors:  Da-Jiang Xin; Guo-Dong Shen; Jian Song
Journal:  Int J Clin Exp Pathol       Date:  2015-08-01

Review 2.  Association of genetic polymorphisms with osteosarcoma risk: a meta-analysis.

Authors:  Zhenyu Bian; Qifang He; Xuepeng Wang; Maoqiang Li; Liulong Zhu
Journal:  Int J Clin Exp Med       Date:  2015-06-15

3.  Rho GTPase-activating protein 35 rs1052667 polymorphism and osteosarcoma risk and prognosis.

Authors:  Jinmin Zhao; Hua Xu; Maolin He; Zhe Wang; Yang Wu
Journal:  Biomed Res Int       Date:  2014-07-20       Impact factor: 3.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.